Robert Carlin, MD
Dermatopathology · Laguna Hills, CANPI 1942368949
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,570 of the $1,920 with a category attached, or 81.8%. 14 manufacturers reported payments, led by Pfizer at 31.4% of the total.
Across 62 payments — averaging $30.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$602
- Johnson & Johnson$457
- Biofrontera Inc.$425
- Revance Therapeutics, Inc.$127
- Amgen$79
- Novartis$58
- plus $172 from 8 others
What the payments were for
- Speaking & faculty fees$35018%
- Food & beverage$1,57082%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 22 | $602 |
| Johnson & Johnson | 16 | $457 |
| Biofrontera Inc. | 2 | $425 |
| Revance Therapeutics, Inc. | 7 | $127 |
| Amgen | 3 | $79 |
| Novartis | 3 | $58 |
| Sanofi | 2 | $44 |
| LEO Pharma Inc. | 1 | $26 |
| AbbVie | 1 | $25 |
| Incyte Corporation | 1 | $24 |
| Galderma Laboratories, L.p. | 1 | $17 |
| Boston Scientific | 1 | $16 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $12 |
| EPI Health, LLC | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMELUZ$350
- BF-RhodoLED$350
How this compares
$1,920 in reported general payments places this provider in the 70th percentile of 76 dermatopathology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gentamicin Sulfate | 70 | $2,839 |
| CiclopiroxCiclopirox Olamine | 124 | $1,467 |
| Mupirocin | 166 | $1,250 |
| MupirocinMupirocin Calcium | 11 | $800 |
| Fluticasone Propionate | 55 | $752 |
| Acyclovir | 37 | $660 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 30 | $552 |
| Imiquimod | 43 | $444 |
| Doxycycline Monohydrate | 24 | $328 |
| Finasteride | 15 | $294 |
| Anastrozole | 29 | $89 |
Paid to pharmacies, not to this prescriber.
Other dermatopathology in Laguna Hills
- Mahsa AbdollahiLaguna Hills$5K
- Christiane QuerfeldDuarte$107K
- Brittney de ClerckLos Angeles$56K
- Brook Brouhala Jolla$20K
- Vishwas ParekhDuarte$13K
- Susan Detwilerla Jolla$7K
- Mandy Ramanila Canada$7K
- Curt VogelEncinitas$7K
- Karen Sherwoodla Canada$6K
- John Honchla Canada$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.